Literature DB >> 29712705

Response by Lytvyn et al to Letter Regarding Article, "Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials".

Yuliya Lytvyn1,2, Petter Bjornstad3, Jacob A Udell4,5,2, Julie A Lovshin1,6,2, David Z I Cherney1,2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29712705      PMCID： PMC5933438          DOI： 10.1161/CIRCULATIONAHA.117.033238

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  5 in total

Review 1.  Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes-2015 Interim Update.

Authors:  William Harper; Maureen Clement; Ronald Goldenberg; Amir Hanna; Andrea Main; Ravi Retnakaran; Diana Sherifali; Vincent Woo; Jean-François Yale; Alice Y Y Cheng
Journal:  Can J Diabetes       Date:  2015-08       Impact factor: 4.190

Review 2.  Perioperative Considerations for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes.

Authors:  Sharon C Peacock; Julie A Lovshin; David Z I Cherney
Journal:  Anesth Analg       Date:  2018-02       Impact factor: 5.108

Review 3.  SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.

Authors:  Ronald M Goldenberg; Lori D Berard; Alice Y Y Cheng; Jeremy D Gilbert; Subodh Verma; Vincent C Woo; Jean-François Yale
Journal:  Clin Ther       Date:  2016-12       Impact factor: 3.393

4.  Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting.

Authors:  Sharon C Peacock; Julie A Lovshin
Journal:  Can J Anaesth       Date:  2017-11-20       Impact factor: 5.063

Review 5.  Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Jacob A Udell; Julie A Lovshin; David Z I Cherney
Journal:  Circulation       Date:  2017-10-24       Impact factor: 29.690
  5 in total
  1 in total

1.  Attenuation of Adverse Postinfarction Left Ventricular Remodeling with Empagliflozin Enhances Mitochondria-Linked Cellular Energetics and Mitochondrial Biogenesis.

Authors:  Yang Song; Chengqun Huang; Jon Sin; Juliana de F Germano; David J R Taylor; Reetu Thakur; Roberta A Gottlieb; Robert M Mentzer; Allen M Andres
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.